Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases and Medical Microbiology
Volume 2019, Article ID 9351801, 7 pages
https://doi.org/10.1155/2019/9351801
Research Article

Rifabutin and Furazolidone Could Be the Candidates of the Rescue Regimen for Antibiotic-Resistant H. pylori in Korea

1Department of Gastroenterology, Gil Medical Center, Gachon University, Incheon, Republic of Korea
2Department of Gastroenterology, Asan Medical Center, Ulsan University, Seoul, Republic of Korea
3Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, Republic of Korea

Correspondence should be addressed to Jun-Won Chung; moc.latipsohlig@neergrd

Received 1 April 2019; Revised 20 June 2019; Accepted 24 June 2019; Published 10 July 2019

Guest Editor: Teresa Fasciana

Copyright © 2019 Youn I Choi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Savoldi, E. Carrara, D. Y. Graham, M. Conti, and E. Tacconelli, “Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in world health organization regions,” Gastroenterology, vol. 155, no. 5, pp. 1372.e17–1382.e17, 2018. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Kekilli, I. Onal, S. Ocal, Z. Dogan, and A. Tanoglu, “Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for Helicobacter pylori,” Saudi Journal of Gastroenterology, vol. 22, no. 5, pp. 366–369, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. T. C. G. Fasciana, C. Capra, S. Zambuto et al., “Helicobacter pylori and epstein-barr co-infection in gastric disease,” Pharmacologyonline, vol. 1, pp. 73–82, 2017. View at Google Scholar
  4. R. Pellicano, R. M. Zagari, S. Zhang, G. M. Saracco, and S. F. Moss, “Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018,” Minerva Gastroenterologica e Dietologica, vol. 64, no. 3, pp. 310–321, 2018. View at Google Scholar
  5. Y.-T. Kuo, J.-M. Liou, E. M. El-Omar et al., “Primary antibiotic resistance in Helicobacter pylori in the asia-pacific region: a systematic review and meta-analysis,” Lancet Gastroenterology & Hepatology, vol. 2, no. 10, pp. 707–715, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Hu, Y. Zhu, and N.-H. Lu, “Primary antibiotic resistance of Helicobacter pylori in China,” Digestive Diseases and Sciences, vol. 62, no. 5, pp. 1146–1154, 2017. View at Publisher · View at Google Scholar · View at Scopus
  7. J. W. Chung, S. Y. Kim, H. J. Park, C. S. Chung, H. W. Lee, and S. M. Lee, “In vitro activity of diphenyleneiodonium toward multidrug-resistant Helicobacter pylori strains,” Gut and Liver, vol. 11, no. 5, pp. 648–654, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Malfertheiner, F. Megraud, C. A. O’Morain et al., “Management of Helicobacter pylori infection-the maastricht v/florence consensus report,” Gut, vol. 66, no. 1, pp. 6–30, 2017. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Fasciana, C. Cala, C. Bonura, E. Di Carlo, D. Matranga, and G. Scarpulla, “Resistance to clarithromycin and genotypes in Helicobacter pylori strains isolated in Sicily,” Journal of Medical Microbiology, vol. 64, no. 11, pp. 1408–1414, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. S. W. Lee, H. J. Kim, and J. G. Kim, “Treatment of Helicobacter pylori infection in Korea: a systematic review and meta-analysis,” Journal of Korean Medical Science, vol. 30, no. 8, pp. 1001–1009, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Auesomwang, M. Maneerattanaporn, W. D. Chey, P. Kiratisin, S. Leelakusolwong, and T. Tanwandee, “Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication,” Journal of Gastroenterology and Hepatology, vol. 33, no. 11, pp. 1822–1828, 2018. View at Publisher · View at Google Scholar · View at Scopus
  12. J. S. Kim, B. W. Kim, S. J. Hong, J. I. Kim, K. N. Shim, and J. H. Kim, “Sequential therapy versus triple therapy for the first line treatment of Helicobacter pylori in Korea: a nationwide randomized trial,” Gut and Liver, vol. 10, no. 4, pp. 556–561, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. J. P. Gisbert, “Review: second-line rescue therapy of helicobacter pylori infection,” Therapeutic Advances in Gastroenterology, vol. 2, no. 6, pp. 331–356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. W. Ko, Y. J. Kim, W. C. Chung, and S. J. Lee, “Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: systemic review and meta-analysis,” Helicobacter, vol. 24, no. 2, Article ID e12565, 2019. View at Publisher · View at Google Scholar · View at Scopus
  15. J. W. Lee, N. Kim, J. M. Kim, R. H. Nam, H Chang, and J. Y. Kim, “Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012,” Helicobacter, vol. 18, no. 3, pp. 206–214, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. J. W. Chung, Y. K. Jung, Y. J. Kim et al., “Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial,” Journal of Gastroenterology and Hepatology, vol. 27, no. 11, pp. 1675–1680, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. J. W. Chung, G. H. Lee, J. Y. Jeong, S. M. Lee, J. H. Jung, and K. D. Choi, “Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance,” Journal of Gastroenterology and Hepatology, vol. 27, no. 3, pp. 493–497, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Fujioka, N. Aoyama, K. Sakai, Y. Miwa, M. Kudo, and J. Kawashima, “A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan,” Journal of Gastroenterology, vol. 47, no. 3, pp. 276–283, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. W. D. Chey, G. I. Leontiadis, C. W. Howden, and S. F. Moss, “ACG clinical guideline: treatment of Helicobacter pylori infection,” American Journal of Gastroenterology, vol. 112, no. 2, pp. 212–239, 2017. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Lee, S. N. Hong, B. H. Min, J. H. Lee, P. L. Rhee, and Y. C. Lee, “Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea,” Digestive and Liver Disease, vol. 47, no. 2, pp. 114–118, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. S. G. Kim, H. K. Jung, H. L. Lee, J. Y. Jang, H. Lee, and C. G. Kim, “Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition,” Journal of Gastroenterology and Hepatology, vol. 29, no. 7, pp. 1371–1386, 2014. View at Google Scholar
  22. L. Jonaitis, R. Pellicano, and L. Kupcinskas, “Helicobacter pylori and nonmalignant upper gastrointestinal diseases,” Helicobacter, vol. 23, Article ID e12522, 2018. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Suzuki and J. Matsuzaki, “Helicobacter pylori eradication failure may have confounded the recent large-scale health database study that showed proton pump inhibitors increase gastric cancer risk,” Gut, vol. 67, no. 11, pp. 2071-2072, 2018. View at Publisher · View at Google Scholar · View at Scopus
  24. P. D. Midolo, J. M. Bell, J. R. Lambert, J. D. Turnidge, and M. L. Grayson, “Antimicrobial resistance testing of Helicobacter pylori: a comparison of etest and disk diffusion methods,” Pathology, vol. 29, no. 4, pp. 411–414, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Heep, D. Beck, E. Bayerdorffer, and N. Lehn, “Rifampin and rifabutin resistance mechanism in Helicobacter pylori,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 6, pp. 1497–1499, 1999. View at Publisher · View at Google Scholar
  26. J. K. Akada, M. Shirai, K. Fujii, K. Okita, and T. Nakazawa, “In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 5, pp. 1072–1076, 1999. View at Publisher · View at Google Scholar
  27. G. Fiorini, A. Zullo, N. Vakil, I. M. Saracino, C. Ricci, and V. Castelli, “Rifabutin triple therapy is effective in patients with multidrug-resistant strains of Helicobacter pylori,” Journal of Clinical Gastroenterology, vol. 52, no. 2, pp. 137–140, 2018. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Zhuge, Y. Wang, S. Wu, R. L. Zhao, Z. Li, and Y. Xie, “Furazolidone treatment for Helicobacter Pylori infection: a systematic review and meta-analysis,” Helicobacter, vol. 23, no. 2, Article ID e12468, 2018. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Bravo, A. Hoare, C. Soto, M. A. Valenzuela, and A. F. Quest, “Helicobacter pylori in human health and disease: mechanisms for local gastric and systemic effects,” World Journal of Gastroenterology, vol. 24, no. 28, pp. 3071–3089, 2018. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Sung, N. Kim, Y. H. Park et al., “Rifabutin-based fourth and fifth-line rescue therapy in patients with for Helicobacter pylori eradication failure,” Korean Journal of Gastroenterology, vol. 69, no. 2, pp. 109–118, 2017. View at Publisher · View at Google Scholar
  31. M. H. Jeong, J.-W. Chung, S. J. Lee et al., “Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori,” Korean Journal of Gastroenterology, vol. 59, no. 6, pp. 401–406, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. A. F. Ciccaglione, R. Tavani, L. Grossi, L. Cellini, L. Manzoli, and L. Marzio, “Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third-line treatment of Helicobacter pylori infection: two pilot studies,” Helicobacter, vol. 21, no. 5, pp. 375–381, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Mori, H. Suzuki, J. Matsuzaki et al., “Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study,” United European Gastroenterology Journal, vol. 4, no. 3, pp. 380–387, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. H. C. Lim, Y. J. Lee, B. An, S. W. Lee, Y. C. Lee, and B. S. Moon, “Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori,” Helicobacter, vol. 19, no. 6, pp. 455–461, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Mohammadi, B. Attaran, R. Malekzadeh, and D. Y. Graham, “Furazolidone, an underutilized drug for H. pylori eradication: lessons from Iran,” Digestive Diseases and Sciences, vol. 62, no. 8, pp. 1890–1896, 2017. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Xie, Y. Zhu, H. Zhou, Z. F. Lu, Z. Yang, and X. Shu, “Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection,” World Journal of Gastroenterology, vol. 20, no. 32, pp. 11415–11421, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. J. J. Kim, R. Reddy, M. Lee, J. G. Kim, F. A. El-Zaatari, and M. S. Osato, “Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea,” Journal of Antimicrobial Chemotherapy, vol. 47, no. 4, pp. 459–461, 2001. View at Publisher · View at Google Scholar
  38. N. Almeida, J. M. Romaozinho, M. M. Donato, C. Luxo, O. Cardoso, and M. A. Cipriano, “Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study,” Helicobacter, vol. 19, no. 2, pp. 90–97, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Lorusso, M. P. Caleca, C. Bellavia, D. Pistoia, S. Gallina, and R. Speciale, “The EBV-DNA can be used as a diagnostic and follow-up parameter of the rhinopharyngeal tumors in the non-endemic population of the western sicily,” Indian Journal of Otolaryngology and Head & Neck Surgery, pp. 1–5, 2018. View at Publisher · View at Google Scholar · View at Scopus